Clinical Trial Update: Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anakinra to prevent severe CAR-T cell-related encephalopathy in patients with recurrent or refractory diffuse large B-cell lymphoma. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma

Drugs mentioned

• KINERET (ANAKINRA)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma | Phase 2 | Status: TERMINATED